Skip to content
Study details
Enrolling now

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Takeda
NCT IDNCT06095128ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

65

Study length

about 3.1 years

Ages

18–65

Locations

40 sites in AL, AZ, CA +19

What this study is about

Researchers are testing whether a treatment with vedolizumab and tofacitinib is effective for adults with ulcerative colitis. The trial also explores the effect of vedolizumab alone after this combined treatment.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Tofacitinib
  • 2.Take Vedolizumab

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
OralInjection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

tofacitinib, vedolizumab

Drug routes

oral (Oral Tablet), injection, intravenous

Endpoints

Secondary: Change in C-Reactive Protein Levels (CRP) From Baseline, Change in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Score From Baseline, Number of Participants With Adverse Events (AEs), Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs)

Body systems

Gastroenterology